Faeth Therapeutics, Inc. Common Stock
FTHStock
$17.82+142.17%52W
Market Cap$19.50M
P/E—
Div yield—
Beta-0.16
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)72.46%
Price vs S&P 500 (4W)-15.62%
VGM Score66.38
Market Capitalization$19.50M
About
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.